Cipla gets USFDA EIR for Invagen manufacturing facility
New Delhi: Homegrown pharma major Cipla on Tuesday said it has received a report from the US health regulator indicating closure of the inspection at its US Invagen manufacturing facility.
"Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019, to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection," Cipla said in a filing to BSE.
The shares of Cipla were trading at Rs 463.20 a piece on BSE in morning trade, down 0.31 per cent from the previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd